Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pDNA-encoding Emm55 autologous cancer cell vaccine IFx-Hu2.0

A whole cell cancer vaccine composed of irradiated autologous whole tumor cells that are transfected, ex vivo, with a plasmid DNA encoding the highly immunogenic Streptococcus pyogenes (S. pyogenes) bacterial antigen Emm55, with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IFx-Hu2.0, the tumor cells expressing the Emm55 bacterial antigen on their cell surface are taken up and processed by antigen-presenting cells (APCs), thereby presenting both the Emm55 and the patient-specific tumor-associated antigens (TAAs) to the immune system. This activates the immune system to elicit a tumor antigen-specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TAAs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous cancer cell-transfected with plasmid DNA encoding for Emm55 Streptococcal antigen IFx-Hu2.0
pDNA autologous cancer cell vaccine IFx-Hu2.0
plasmid DNA autologous cancer vaccine IFx-Hu2.0
plasmid DNA vaccine encoding S. pyogenes Emm55 protein
Foreign brand name:ImmuneFx
Code name:IFx-Hu2.0
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search